November 11, 2018 SITC 2018 – Nektar’s big reveal falls flat The company struggles to move the needle at the SITC meeting with an up-to-date cut of its first-line melanoma trial of NKTR-214 and Opdivo.
November 06, 2018 How many million-dollar drugs can health systems tolerate? Novartis's $4m price target for AVXS-101 fuels concerns that too many new gene therapies could overburden payers without a hard look at how they are financed.
